drugset / Trial / NCT03891979
Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
A multi-institutional, single arm pilot study of antibiotics and pembrolizumab for the treatment of surgically resectable pancreatic cancer. The primary purpose of this study is to determine the change in immune activation in pancreatic tumor tissue following treatment with antibiotics and pembrolizumab.
Timeline
- Start
- 2019-06-25
- Primary completion
- 2020-06-01
- Completion
- 2020-06-01
Outcome
Outcome not reported
Stopped: “Suspended due to Primary Investigator's decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ciprofloxacin | Small molecule | 500 mg | Oral |
| Subject | Metronidazole | Small molecule | 500 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |